Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L02 ENDOCRINE THERAPY
L02B HORMONE ANTAGONISTS AND RELATED AGENTS
L02BB Anti-androgens
L02BB05 Apalutamide
D11040 Apalutamide (JAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antiandrogens
Apalutamide
D11040 Apalutamide (JAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11040 Apalutamide (JAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01591 Androgen receptor antagonist
DG01624 Flutamide-type antiandrogen
D11040 Apalutamide
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
D11040 Apalutamide
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D11040 Apalutamide
Metabolizing enzyme inducer
DG02886 CYP2C9 inducer
D11040 Apalutamide
DG02885 CYP2C19 inducer
D11040 Apalutamide
DG02853 CYP3A/CYP3A4 inducer
DG01635 CYP3A4 inducer
D11040 Apalutamide
Transporter inducer
DG01893 ABCB1 inducer
D11040 Apalutamide
DG02910 ABCG2 inducer
D11040 Apalutamide
DG02911 SLCO1B1 inducer
D11040 Apalutamide
Drug classes [BR:br08332]
Antineoplastic
DG01591 Androgen receptor antagonist
D11040 Apalutamide
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Estrogen like receptors
3-Ketosteroid receptor
NR3C4 (AR)
D11040 Apalutamide (JAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11040
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11040
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11040
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11040
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11040
Drug transporters
D11040